Aims: Participant drop out is a major barrier to high-quality patient-reported outcome (PRO) data analysis in cancer research as patients with worsening health are more likely to dropout. To test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia. Methods: This analysis included 619 participants, stratified by time of dropout, from the Australian Ovarian Cancer Study -Quality of Life substudy, in which participants completed PRO questionnaires at threemonthly intervals for 21 months. Trends in PROs over time were examined. Pearson correlations examined the relationship between time of dropout and baseline PROs. Multiple linear regression models including age, disease stage and time since diagnosis examined relationships between baseline and final PRO scores, and final PRO scores and dropout group. Results: Participants who dropped out earlier had significantly worse baseline HRQOL (p < 0.0001) and higher depression (p < 0.0001). For all five PROs, final scores were significantly associated with baseline scores (p < 0.0001). Time of dropout was significantly associated with final HRQOL (p = 0.003), anxiety (p = 0.05), depression (p = 0.02) and optimism (p = 0.02) scores. Depression, HRQOL and anxiety worsened at a faster rate overtime in dropouts than study completers. Conclusions: Poorer HRQOL and higher depression at baseline, and final HRQOL, anxiety, depression and optimism scores were predictive of time of dropout. These results highlight the importance of collecting auxiliary data to inform careful and considered handling of missing PRO data during analysis, interpretation and reporting.
However, a major barrier to high-quality PRO data analysis is missing data; particularly unit non-response -when PRO data is missing for a whole time-point. Unit non-response at the patient level can further be classified into three groups: (i) monotone missing data refers to patient dropout or attrition, i.e. a patient has completed initial PRO assessments but then drops out and is never observed again [2] [3] [4] ; (ii) intermittent missing data occurs where a patient is observed again after a missed assessment [2] [3] [4] [5] [6] ; or (iii) missing initial PRO data due to late study entry. 4 The focus of this article is monotone missing PRO data, in particular to illustrate the bias that can arise in data analysis and interpretation depending on how monotone missing data are addressed. Commonly used approaches such as excluding patients with missing data or using simple imputation can lead to biased interpretation. 7 For example, if patients who drop out have greater health decline, these approaches may lead to a false conclusion that the sample had better outcomes than was the true case. This is because PROs are often predictive of survival. 8 Experts recommend addressing missing PRO data using tailored imputation methods, based on scrutiny of individual data and consideration of why PRO data is missing (the "missing data mechanism"). 2, 9 [For a detailed discussion we direct readers to the following sources]. 2, 6, 10 Predictors of missing PRO data have been studied in a range of research settings. In cancer clinical trials, patients with worse baseline HRQOL 6 and worse baseline symptom, emotional and physical functioning scores 5 exhibited higher rates of dropout. HIV-positive patients with higher depressive symptoms were more likely to dropout of a pain management study, regardless of their illness severity. 11 In a review of chronic headache, stress management and weight reduction studies, psychological variables were often predictive of attrition. 12 PRO data may be missing for a diverse range of reasons in disease population-based cohort studies, owing to participant heterogeneity in disease stage or treatments, as well as difficulties in following up such large numbers of patients from diverse recruiting sites over the life of the study. Ovarian cancer provides a good example of the complexities inherent in assessing PROs longitudinally in population cohort studies. Approximately 75% of women with ovarian cancer present with advanced disease, due to limitations of effective screening methods for those at population risk and/or absence or vagueness of symptoms during earlier stages of the disease. 13, 14 Ovarian cancer treatment usually involves debulking surgery with neoadjuvant or adjuvant chemotherapy, and in many cases, maintenance therapy and therapy for recurrent disease.
14 The overall expected 5-year survival rate is only 44% 15 ; however, survival rates differ significantly depending on stage at diagnosis: with up to 95% of patients with stage I disease surviving 5 years compared to <30% with advanced disease. 13 Thus, in a population-based cohort study of women with ovarian cancer, many enrolled participants will be expected to die during follow up, resulting in monotone missing PRO data. However, monotone missing data may also result from reasons other than death, including health-and non-health-related factors, further complicating decisions about how missing data should be handled for analysis. 16 To our knowledge, the relationship between PROs and dropout has not previously been studied in ovarian cancer population-based cohort studies.
AIMS
Based on the expectation that patients with worse HRQOL would be more likely to drop out earlier than other patients, the primary aim of the present analysis was to compare the HRQOL of ovarian cancer patients in a population-based cohort study by time of dropout. Our secondary aim was to compare how patients differed by time of dropout on other key PROs, namely anxiety, depression, optimism and insomnia. These variables were chosen as we speculated they could impact a patient's willingness and ability to continue completing researchbased PROs in the context of their illness. We hypothesized that patients who dropped out of the trial would have poorer HRQOL, higher anxiety, higher depression, lower optimism and more insomnia than those who continued to final assessment.
MATERIALS AND METHODS
The Australian ovarian cancer study and quality of life substudy Existing PRO data from an ovarian cancer populationbased cohort study: the Australian Ovarian Cancer Study (AOCS) QOL substudy [17] [18] [19] was utilized for this analysis. Details of the parent AOCS 17 and QOL substudy 18, 19 sampling and recruitment methods are detailed elsewhere. In brief, the AOCS recruited a population-based sample of women aged 18-79 years newly diagnosed with primary epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) between 2002 and 2006 through treatment centers and state cancer registries. 17 The QOL substudy commenced in 
PRO measures
The PROs included in this analysis include the global HRQOL score of the Functional Assessment of Cancer Therapy -Ovarian Cancer (FACT-O version 4) questionnaire, 20 anxiety and depression using the two subscales of the Hospital Anxiety and Depression Scale (HADS) 21 ; optimism using the Life Orientation TestRevised (LOT-R) 22 ; and insomnia using the Insomnia Severity Index (ISI).
23

Participants
AOCS QOL substudy participants with confirmed stage II-IV ovarian cancer who completed at least one PRO assessment are included in this analysis. We excluded participants with stage I disease due to their different assessment schedule, and participants whose disease stage was unclear from available data.
Analysis
Participants were stratified into eight groups according to the number of PRO assessment time points completed. For example, participants who completed two PRO assessments, at study entry and 3 months later, were grouped together (T2 group), and participants who completed six consecutive assessments were grouped together (T6). There were 37 intermittent missing values in our dataset, which were imputed using a single imputation of the expectation-maximization algorithm. This represents less than 1% (37/3820) observations in our analysis.
For each PRO, the mean score for each group at each time point was graphed. Multiple linear regression was used to see if the final measurement of each PRO was associated with the initial (baseline) measurement and the dropout group. Age, disease stage and time since diagnosis (accessed via the AOCS parent study) were also included in the model. We computed the Pearson's correlation between baseline score for each PRO variable and participant dropout group and report this, as it is more interpretable than regression coefficients on different scales. All analyses were performed in SAS version 9.4.
RESULTS
A total of 619 participants are included in this analysis and almost half (n = 288, 47%) of these participants had monotone missing PRO data. Table 1 shows the number of participants who dropped out after each scheduled PRO assessment, forming the analysis groups for this analysis. Most women (87%) had stage III/IV disease at diagnosis, n = 159 (26%) participants' disease progressed during the study and n = 243 (39%) died within the study period.
Health-related quality of life Figure 1 shows that patients who dropped out of the study earlier had worse baseline HRQOL on average and more severe HRQOL decline over time, until they ultimately dropped out. The steepest declines in mean HRQOL occurred between the two final Figure 2 shows mean anxiety scores for each dropout group. In all groups, the mean anxiety score was in the normal range throughout the study, with the exception of the T6 group whose average anxiety score was in the subclinical range throughout. The T8 group experienced the least fluctuation in anxiety scores and maintained lower mean anxiety throughout the study, although we did not test this claim statistically. Baseline anxiety score was not significantly correlated with time of dropout ρ = −0.05, p = 0.24, 95% CI [−013, 0.03]; however, final anxiety score was significantly associated with time of dropout (p = 0.05) in the regression model including age, disease stage and time since diagnosis. Baseline anxiety was also significantly associated with final anxiety score in the model (p < 0.0001). Figure 3 shows mean depression scores for each dropout group. The T8 group maintained lowest mean depression throughout the study. Groups T1, T2, T3 and T6 entered the study with higher depression scores, and continued to experience higher depression than other groups until their time of dropout. T6 was the only group where the mean score reached the HADS sub-clinical depression threshold, which occurred at 12-month follow-up. All groups experienced slight increases in depression over time, and most groups experienced steepest increases in depression between their final two PRO assessments. Pearson's correlation showed that baseline HADS depression score was correlated with time of drop out ρ = −0.17, p < 0.0001, 95% CI [−0.24, −0.09]. The regression model indicated that final depression score was significantly associated with baseline depression (p < 0.0001) and dropout group (p = 0.02). Figure 4 shows mean optimism scores for each dropout group. Groups T4, T5, T7 and T8 reported highest optimism, whereas groups T2 and T6 reported lowest mean 
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DISCUSSION
This study examines the relationship between PROs and time of dropout in a large longitudinal cohort study of women with ovarian cancer, specifically examining the relationship between PRO scores and dropout, and the change in PROs overtime between participants stratified by time of dropout. Participants who dropped out earlier had significantly worse baseline HRQOL and depression. They also had steeper declines in HRQOL and increases in depression overtime, particularly in the assessments prior to dropout, compared to those who completed more PRO assessments. Similar patterns were evident for anxiety, and to a lesser extent, optimism. Insomnia appeared unrelated to dropout in this cohort.
Final PRO scores, namely HRQOL, anxiety, depression, optimism and insomnia scores, were significantly associated with corresponding baseline PRO scores -when patient age, ovarian cancer stage and time since diagnosis were controlled for. Final HRQOL, anxiety, depression and optimism scores were also associated with time of dropout. These patterns indicate a relationship between PROs and dropout in this cohort. 6, 9 As demonstrated by this study, not all PROs are predictive of dropout. The PROs that are predictive are likely to vary according to the clinical context of the population under study, and the study design and aims. The ability to predict participants at higher risk of dropping out based on baseline PRO scores can potentially assist researchers in developing strategies to improve PRO data completeness. Based on our finding that depression was predictive of dropout, we question whether earlier uptake of psychosocial referral options in patients with high baseline depression scores might improve PRO completion rates, as well as reducing symptoms of depression. This may be an interesting direction for future research.
As already noted, HRQOL has predicted survival in other studies, 8 and in such cases, missing HRQOL data are not always preventable. Thus, poor baseline HRQOL scores should prompt researchers to ensure auxiliary data is collected to assist in determining the missing data mechanism. Indeed, we and others recommend that auxiliary data, such as clinician-rated Karnovsky or ECOG status, should be collected in all PRO studies from the very beginning. 6, 24 Additionally, having site staff record reasons for incomplete PRO questionnaires using standardized forms can further inform choice of imputation method. 24 Many examples of such forms have previously been published. 4, 25, 26 A recent systematic review collated strategies for reducing the problem of missing data, and highlighted the importance of clear reporting, including a comparison of baseline characteristics of participants with and without missing data, presentation of sensitivity analyses, a discussion of reasons for missing data and how it may impact the generalizability of findings. 24 The analysis of samples with missing PRO data is a more difficult problem, requiring expert statistical and clinical input based on the specific research question and clinical context. A detailed discussion of potential analysis methods is beyond the scope of this paper; however, as a starting point, the methodology used in this study to identify patterns in missing PRO data is one useful way to determine the potential missing data mechanism, which is a prerequisite to making a sensible choice of imputation method/s for missing PRO data. Additional methods are also available. 3, 6, 10 Although a large number of participants in our study experienced disease progression or died during the follow-up period, it is unlikely that all missing PRO data was due to worsening health status. Indeed, other cancer studies have reported logistic and administrative factors as a major cause of missing PRO data; variables often unrelated to patients' health. 25 Furthermore, other variables may be influencing dropout. For example, despite remaining in the study for 15 months, the T6 group experienced negative symptoms across all domains tested over the study's duration. Possibly their lower optimism, and higher depression and anxiety at baseline was reflecting time since diagnosis, disease severity (86% had stage III disease at diagnosis) and treatment status. These PRO domains also worsened overtime in the T6 group. Although this may reflect a chance finding, it does underline the importance of not underestimating the influence of sampling, disease and treatment trajectory when examining missing PRO data.
The QOL study sample were recruited via an existing population-based cohort study involving women with ovarian cancer, at any stage of treatment, and the ensuing lack of a uniform time of entry into the study complicates data analysis and interpretation. However, it is ideal for the purpose of illustrating the importance of considering the way in which monotone missing PRO data is dealt with and interpreted. Thus, our results showing large differences in PROs may be exaggerated compared to those observable in clinical trials or other designs with a more homogenous trial sample and baseline assessment point. Nevertheless, our analyses of final PRO scores which controlled for clinical variability showed significant associations with baseline PROs and time of dropout. Additionally, our results are similar to findings of a recent advanced stage renal carcinoma study, in which both the control and experimental group patients who dropped out earlier had worse baseline HRQOL. 6 Our findings cause us to echo the recommendations of others. Complete case analyses (without prior imputation of missing PRO data) should be avoided for PRO analyses, particularly in cancer research samples where a decline in PROs may be expected over the life of the study, or in studies with high missing data rates.
2,3,6,10,26 Using Figure 1 as an example, a complete case analysis would include only the Group T8 line, thus missing all of the patients who dropped out and had worse HRQOL over the study duration. Apart from a significant reduction in sample size (n = 331 compared to n = 619) and statistical power, the results would falsely indicate that HRQOL was stable, and high, over time. We also recommend that imputation and analysis decisions are informed by close scrutiny of PRO data, including rates and reasons for missing data. These decisions should be reported and justified in research publications to facilitate interpretability and generalizability of findings.
In conclusion, baseline HRQOL and depression scores were predictive of time of dropout and trends in HRQOL, anxiety and depression overtime differed by time of dropout in this population-based cohort study of women with ovarian cancer. When controlling for age, cancer stage and time since diagnosis, final HRQOL, anxiety, depression and optimism scores were predictive of time of dropout. Significant associations between baseline and final PRO scores were observed for patient-reported HRQOL, depression, anxiety, optimism and insomnia, indicating that missing data were informative in this cohort. These results highlight the importance of careful and considered handling of missing PRO data during analysis, interpretation and reporting, as well as the importance of implementing strategies to minimize the problem of missing PRO data, such as collecting auxiliary data and recording reasons for missing PRO data.
